Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 3/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.30 |
| ▸ | MMP7 | P09237 | 2/20 | 0.30 |
| ▸ | MMP8 | P22894 | 2/20 | 0.30 |
| ▸ | MMP13 | P45452 | 2/20 | 0.30 |
| ▸ | MMP1 | P03956 | 2/20 | 0.30 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3656186 | 0.86 | APP (0.34) | APPL3MBTL1KMT2ARAB9AALDH1A1 | |
| SCHEMBL3659956 | 0.85 | APP (0.33) | APPL3MBTL1 | |
| SCHEMBL3656907 | 0.84 | PTGS2 (0.34) | APPHTR1AL3MBTL1KMT2ARAB9A | |
| SCHEMBL3664404 | 0.84 | SMN1; SMN2 (0.34) | APPL3MBTL1RAB9A | |
| SCHEMBL3662005 | 0.83 | MAPT (0.41) | APPHTR1A | |
| SCHEMBL3660239 | 0.82 | L3MBTL1 (0.35) | APPHTR1AL3MBTL1RAB9A | |
| SCHEMBL3663858 | 0.81 | PTGS2 (0.36) | APPL3MBTL1KMT2AALDH1A1PTGS2 | |
| SCHEMBL3661499 | 0.81 | L3MBTL1 (0.34) | APPHTR1AL3MBTL1KMT2ARAB9A | |
| SCHEMBL3662973 | 0.80 | PTGS2 (0.38) | APPPTGS2 | |
| SCHEMBL3758606 | 0.76 | RPS6KA1 (0.36) | HTR1AL3MBTL1PDE4BMMP2ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHIEMCAL COMPANY LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2215062-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | Sumitomo Chemical Company, Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009069792-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311790-A1 | AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME | ATL3, NAT1, C5 | APP 2380/4885HTR1A 2686/4885L3MBTL1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.